Should the FDA ignore political pressure from Trump and RFK Jr. and reject leucovorin for autism despite public demand?
FDA vs. Politicians: Will Leucovorin Be Approved for Autism?
Former President Donald Trump and Robert F. Kennedy Jr. recently promoted leucovorin, an unproven treatment for autism spectrum disorder, claiming it offers a new medical breakthrough. This endorsement came despite a lack of robust clinical data supporting its efficacy. A new study reveals that many families, driven by these high-profile political figures, have begun using the drug anyway, even though medical experts consider the evidence insufficient. The controversy highlights the tension between political influence and scientific rigor in healthcare policy. Regulators are now facing intense scrutiny to determine whether to approve the drug based on public pressure or adhere strictly to evidence-based standards. The case of leucovorin serves as a critical test for the FDA's independence. Critics argue that political figures should not dictate medical approvals, while supporters believe families deserve access to potential treatments regardless of bureaucratic hurdles. This situation underscores the growing influence of non-expert voices in defining medical science and public health guidelines.
Options
- Approve it to help desperate families
- Reject it due to lack of scientific evidence
- Demand more rigorous independent studies first
- Let insurance companies decide coverage